87 related articles for article (PubMed ID: 27717544)
1. Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors.
Jadhavar PS; Ramachandran SA; Riquelme E; Gupta A; Quinn KP; Shivakumar D; Ray S; Zende D; Nayak AK; Miglani SK; Sathe BD; Raja M; Farias O; Alfaro I; Belmar S; Guerrero J; Bernales S; Chakravarty S; Hung DT; Lindquist JN; Rai R
Bioorg Med Chem Lett; 2016 Nov; 26(21):5222-5228. PubMed ID: 27717544
[TBL] [Abstract][Full Text] [Related]
2. Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells.
Rosati R; Chen B; Patki M; McFall T; Ou S; Heath E; Ratnam M; Qin Z
Mol Pharmacol; 2016 Sep; 90(3):225-37. PubMed ID: 27382012
[TBL] [Abstract][Full Text] [Related]
3. PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer.
Gravina GL; Marampon F; Muzi P; Mancini A; Piccolella M; Negri-Cesi P; Motta M; Lenzi A; Di Cesare E; Tombolini V; Jannini EA; Festuccia C
Endocr Relat Cancer; 2013 Jun; 20(3):321-37. PubMed ID: 23507703
[TBL] [Abstract][Full Text] [Related]
4. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.
Ai J; Wang Y; Dar JA; Liu J; Liu L; Nelson JB; Wang Z
Mol Endocrinol; 2009 Dec; 23(12):1963-72. PubMed ID: 19855091
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of androgen receptors by NaAsO
Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
[TBL] [Abstract][Full Text] [Related]
6. 4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90α chaperone activity against prostate cancer.
Seidel C; Schnekenburger M; Mazumder A; Teiten MH; Kirsch G; Dicato M; Diederich M
Biochem Pharmacol; 2016 Jan; 99():31-52. PubMed ID: 26549368
[TBL] [Abstract][Full Text] [Related]
7. Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6.
Gibbs A; Schwartzman J; Deng V; Alumkal J
Proc Natl Acad Sci U S A; 2009 Sep; 106(39):16663-8. PubMed ID: 19805354
[TBL] [Abstract][Full Text] [Related]
8. Selectively targeting prostate cancer with antiandrogen equipped histone deacetylase inhibitors.
Gryder BE; Akbashev MJ; Rood MK; Raftery ED; Meyers WM; Dillard P; Khan S; Oyelere AK
ACS Chem Biol; 2013 Nov; 8(11):2550-60. PubMed ID: 24004176
[TBL] [Abstract][Full Text] [Related]
9. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
10. Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function.
Basak S; Pookot D; Noonan EJ; Dahiya R
Mol Cancer Ther; 2008 Oct; 7(10):3195-202. PubMed ID: 18852123
[TBL] [Abstract][Full Text] [Related]
11. Drugging the HDAC6-HSP90 interplay in malignant cells.
Krämer OH; Mahboobi S; Sellmer A
Trends Pharmacol Sci; 2014 Oct; 35(10):501-9. PubMed ID: 25234862
[TBL] [Abstract][Full Text] [Related]
12. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
[TBL] [Abstract][Full Text] [Related]
13. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
[TBL] [Abstract][Full Text] [Related]
14. Histone Deacetylase Inhibition in Prostate Cancer Triggers miR-320-Mediated Suppression of the Androgen Receptor.
Sato S; Katsushima K; Shinjo K; Hatanaka A; Ohka F; Suzuki S; Naiki-Ito A; Soga N; Takahashi S; Kondo Y
Cancer Res; 2016 Jul; 76(14):4192-204. PubMed ID: 27216188
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment.
Zhou M; Zheng H; Li Y; Huang H; Min X; Dai S; Zhou W; Chen Z; Xu G; Chen Y
Aging (Albany NY); 2021 Feb; 13(5):6982-6998. PubMed ID: 33621955
[TBL] [Abstract][Full Text] [Related]
16. HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis.
Ryu HW; Shin DH; Lee DH; Choi J; Han G; Lee KY; Kwon SH
Cancer Lett; 2017 Apr; 391():162-171. PubMed ID: 28153791
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of a selective HDAC6 inhibitor active in neuroblasts.
Zwick V; Simões-Pires CA; Nurisso A; Petit C; Dos Santos Passos C; Randazzo GM; Martinet N; Bertrand P; Cuendet M
Bioorg Med Chem Lett; 2016 Oct; 26(20):4955-4959. PubMed ID: 27650925
[TBL] [Abstract][Full Text] [Related]
18. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.
Liu S; Yuan Y; Okumura Y; Shinkai N; Yamauchi H
Biochem Biophys Res Commun; 2010 Apr; 394(2):297-302. PubMed ID: 20206136
[TBL] [Abstract][Full Text] [Related]
19. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
[TBL] [Abstract][Full Text] [Related]
20. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
